Aditya Menon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aditya Menon has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Charis Eng
Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, USA
1 shared publication - Iris Nira Smith
Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic
1 shared publication - Junyi Liang
Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, USA
1 shared publication - Lynn M. Bekris
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
1 shared publication - Maria Khrestian
Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA
1 shared publication - Matthias Buck
Department of Physiology and Biophysics, Case Western Reserve University, School of Medicine, 10900 Euclid Avenue, Cleveland, Ohio 44106, U. S. A
1 shared publication
Latest Publications
- Open Access
- 6 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9667
A Computational Approach in the Systematic Search of the Interaction Partners of Alternatively Spliced TREM2 Isoforms
Alzheimer’s disease is the most common form of dementia, characterized by the pathological accumulation of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles. Triggering receptor expressed on myeloid cells 2 (TREM2) is increasingly recognized as playing a central role in Aβ clearance and microglia activation in AD. The TREM2 gene transcriptional product is alternatively spliced to produce three different protein isoforms. The canonical TREM2 isoform binds to DAP12 to activate downstream pathways. However, little is known about the function or interaction partners of the alternative TREM2 isoforms. The present study utilized a computational approach in a systematic search for new interaction partners of the TREM2 isoforms by integrating several state-of-the-art structural bioinformatics tools from initial large-scale screening to one-on-one corroborative modeling and eventual all-atom visualization. CD9, a cell surface glycoprotein involved in cell–cell adhesion and migration, was identified as a new interaction partner for two TREM2 isoforms, and CALM, a calcium-binding protein involved in calcium signaling, was identified as an interaction partner for a third TREM2 isoform, highlighting the potential role of cell adhesion and calcium regulation in AD.
- 6 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9667
Open AccessA Computational Approach in the Systematic Search of the Interaction Partners of Alternatively Spliced TREM2 Isoforms
Alzheimer’s disease is the most common form of dementia, characterized by the pathological accumulation of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles. Triggering receptor expressed on myeloid cells 2 (TREM2) is increasingly recognized as playing a central role in Aβ clearance and microglia activation in AD. The TREM2 gene transcriptional product is alternatively spliced to produce three different protein isoforms. The canonical TREM2 isoform binds to DAP12 to activate downstream pathways. However, little is known about the function or interaction partners of the alternative TREM2 isoforms. The present study utilized a computational approach in a systematic search for new interaction partners of the TREM2 isoforms by integrating several state-of-the-art structural bioinformatics tools from initial large-scale screening to one-on-one corroborative modeling and eventual all-atom visualization. CD9, a cell surface glycoprotein involved in cell–cell adhesion and migration, was identified as a new interaction partner for two TREM2 isoforms, and CALM, a calcium-binding protein involved in calcium signaling, was identified as an interaction partner for a third TREM2 isoform, highlighting the potential role of cell adhesion and calcium regulation in AD.